Cardiovascular diseases are leading cause of morbidity and mortality globally. Biomarkers are generally used as an indicator forparticular diseases such as rheumatic and congenital heart diseases and ... Cardiovascular diseases are leading cause of morbidity and mortality globally. Biomarkers are generally used as an indicator forparticular diseases such as rheumatic and congenital heart diseases and cardiac arrhythmia. Cardiac biomarkers are measurable and quantifiable biological parameters. These are specifically used to check the presence or severity of cardiovascular diseases. Cardiac biomarkers are the substances that are released into blood when heart is damaged. These biomarkers are also used for diagnosing and monitoring diseases such as coronary syndrome or cardiac ischemia. The symptoms of these diseases includes chest pain, shortness of breath and nausea that ultimately leads to heart attack or angina. Cardiac biomarker tests helps to detect presence of coronary syndrome and cardiac ischemia to evaluate its severity and diagnosis. Increasing number of cardiovascular diseases drives the overall growth of Cardiac Biomarkers Market. For example, According to World Health Organization, about 17.3 million people died from cardiovascular diseases (CVD) in 2008 and the number is expected to reach 23.3 million by 2030. This increase in number of patients suffering from cardiovascular diseases across the world will boost the global cardiac biomarkers market.However, side effects such as skeletal muscle injury and less specific actions of these biomarkers will restrain the growth of this market. Request to View Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1923 Geographically, North America and Europe dominates the global cardiac biomarkers market due to increasing patient population suffering from cardiovascular diseases (angina pectoris, myocardial infraction and others), lack of physical activity and unhealthy diet. In addition, India, South East Asia and China are the emerging markets for cardiac biomarkers because of rising incidences of coronary artery diseases. The positive initiative by government in Asia-Pacific regions towards healthcare infrastructure may also boost the growth of cardiac biomarkers market in this region. Various key players contributing to the global cardiac biomarkers market comprises Abbott Laboratories, Ortho-Clinical Diagnostics, Inc., Roche Diagnostics Corporation, Alere, Inc., Biosensors International Ltd., Medtronic, Inc., Boston Scientific Corporation and others. Pre-Book Full Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=1923<ype=S Source: Free Articles from ArticlesFactory.com About Us Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge. US Office Contact 90 State Street, Suite 700 Albany, NY 12207 Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Email: [email protected] Website: http://www.transparencymarketresearch.com